isbe-astrazeneca strategic alliance project 26 evaluation of crohn’s disease using t1-weighted...
TRANSCRIPT
![Page 1: ISBE-AstraZeneca Strategic Alliance Project 26 Evaluation of Crohn’s disease using T1-weighted dynamic contrast- enhanced MRI (DCE-MRI) Karl Embleton](https://reader035.vdocuments.site/reader035/viewer/2022062304/56649f455503460f94c663d3/html5/thumbnails/1.jpg)
ISBE-AstraZeneca Strategic Alliance Project 26
Evaluation of Crohn’s disease using T1-weighted dynamic contrast-
enhanced MRI (DCE-MRI)
Karl Embleton
![Page 2: ISBE-AstraZeneca Strategic Alliance Project 26 Evaluation of Crohn’s disease using T1-weighted dynamic contrast- enhanced MRI (DCE-MRI) Karl Embleton](https://reader035.vdocuments.site/reader035/viewer/2022062304/56649f455503460f94c663d3/html5/thumbnails/2.jpg)
Project objectives
• develop an M. R. based imaging technique to provide dynamic contrast enhanced images for investigation of inflammatory bowel disease
• derive disease volume measurements from contrast enhanced images of inflammatory bowel disease
• assess the application of endothelial permeability measurements to inflammatory bowel disease
• assess reproducibility of these measurements and the ability to identify treatment effects
![Page 3: ISBE-AstraZeneca Strategic Alliance Project 26 Evaluation of Crohn’s disease using T1-weighted dynamic contrast- enhanced MRI (DCE-MRI) Karl Embleton](https://reader035.vdocuments.site/reader035/viewer/2022062304/56649f455503460f94c663d3/html5/thumbnails/3.jpg)
• Five patients scanned at present
• 3 with small regions of inflammation• 1 with large region, fistula present• 1 with previous ileostomy
• Each patient scanned once only
Current recruitment
![Page 4: ISBE-AstraZeneca Strategic Alliance Project 26 Evaluation of Crohn’s disease using T1-weighted dynamic contrast- enhanced MRI (DCE-MRI) Karl Embleton](https://reader035.vdocuments.site/reader035/viewer/2022062304/56649f455503460f94c663d3/html5/thumbnails/4.jpg)
512x512x50 axial sense breathold
512x512x25 coronal sense
512x512x128 2mm axial post-contrast WAVE
MRI protocol
256x256x25 morphologicalpost-contrast
256x256x25 morphological fat-satpost-contrast
![Page 5: ISBE-AstraZeneca Strategic Alliance Project 26 Evaluation of Crohn’s disease using T1-weighted dynamic contrast- enhanced MRI (DCE-MRI) Karl Embleton](https://reader035.vdocuments.site/reader035/viewer/2022062304/56649f455503460f94c663d3/html5/thumbnails/5.jpg)
WAVE SENSE image showing inflamed and normal tissue
![Page 6: ISBE-AstraZeneca Strategic Alliance Project 26 Evaluation of Crohn’s disease using T1-weighted dynamic contrast- enhanced MRI (DCE-MRI) Karl Embleton](https://reader035.vdocuments.site/reader035/viewer/2022062304/56649f455503460f94c663d3/html5/thumbnails/6.jpg)
Enhancement curves
-500
500
1500
2500
1 6 11 16 21 26 31 36
Patient 3 Patient 4
time-point
-100
100
300
500
1 6 11 16 21 26 31 36
subcutaneous_ fat
inflamed bowel
artery
non-inflamed small bowel
mesentery
![Page 7: ISBE-AstraZeneca Strategic Alliance Project 26 Evaluation of Crohn’s disease using T1-weighted dynamic contrast- enhanced MRI (DCE-MRI) Karl Embleton](https://reader035.vdocuments.site/reader035/viewer/2022062304/56649f455503460f94c663d3/html5/thumbnails/7.jpg)
Permeability analysis
Standard Toft’s
Enhanced Toft’s with automated AIF
First-pass leakage profile
A model based on that of St Laurence and Lee allowing direct estimation of local tissue blood flow will also be applied
![Page 8: ISBE-AstraZeneca Strategic Alliance Project 26 Evaluation of Crohn’s disease using T1-weighted dynamic contrast- enhanced MRI (DCE-MRI) Karl Embleton](https://reader035.vdocuments.site/reader035/viewer/2022062304/56649f455503460f94c663d3/html5/thumbnails/8.jpg)
Parameter map overlays, patient 4
Kfp WAVE SENSE First pass VP
Ktrans Ve Vp
![Page 9: ISBE-AstraZeneca Strategic Alliance Project 26 Evaluation of Crohn’s disease using T1-weighted dynamic contrast- enhanced MRI (DCE-MRI) Karl Embleton](https://reader035.vdocuments.site/reader035/viewer/2022062304/56649f455503460f94c663d3/html5/thumbnails/9.jpg)
Volume renderings patient 4
Ktrans Ve Vp
Kfp First Pass Vp
![Page 10: ISBE-AstraZeneca Strategic Alliance Project 26 Evaluation of Crohn’s disease using T1-weighted dynamic contrast- enhanced MRI (DCE-MRI) Karl Embleton](https://reader035.vdocuments.site/reader035/viewer/2022062304/56649f455503460f94c663d3/html5/thumbnails/10.jpg)
Volume renderings patient 3
Ktrans Ve Vp
Kfp First Pass Vp
![Page 11: ISBE-AstraZeneca Strategic Alliance Project 26 Evaluation of Crohn’s disease using T1-weighted dynamic contrast- enhanced MRI (DCE-MRI) Karl Embleton](https://reader035.vdocuments.site/reader035/viewer/2022062304/56649f455503460f94c663d3/html5/thumbnails/11.jpg)
0
0.2
0.4
0.6
0.8
1 2 3 4
Ktrans CrohnKtrans non
Mean parameter measurement for whole ROI
0
0.2
0.4
0.6
1 2 3 4
Ve CrohnVe non
0
0.05
0.1
1 2 3 4
Vp CrohnVp non
0
0.1
0.2
0.3
0.4
0.5
0.6
1 2 3 4
Kfp CrohnKfp non
0
0.1
0.2
0.3
1 2 3 4
fp Vp Crohnfp Vp non
Enhanced Toft’s with Ve abd auto AIF
First Pass
![Page 12: ISBE-AstraZeneca Strategic Alliance Project 26 Evaluation of Crohn’s disease using T1-weighted dynamic contrast- enhanced MRI (DCE-MRI) Karl Embleton](https://reader035.vdocuments.site/reader035/viewer/2022062304/56649f455503460f94c663d3/html5/thumbnails/12.jpg)
Cumulative frequency histograms, patient 4, enhanced Toft’s
0
20
40
60
80
100
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9
Ktrans
no
rmal
ised
cu
mu
lati
ve f
req
uen
cy
Crohn's non-inflamed
0
20
40
60
80
100
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9
Ve
no
rmal
ised
cu
mu
lati
ve f
req
uen
cy
Crohn's non-inflamed
![Page 13: ISBE-AstraZeneca Strategic Alliance Project 26 Evaluation of Crohn’s disease using T1-weighted dynamic contrast- enhanced MRI (DCE-MRI) Karl Embleton](https://reader035.vdocuments.site/reader035/viewer/2022062304/56649f455503460f94c663d3/html5/thumbnails/13.jpg)
Cumulative frequency histograms, patient 4, first pass
0
20
40
60
80
100
0.01 0.11 0.21 0.31
Kfp
no
rmal
ised
cu
mu
lati
ve f
req
uen
cy
Crohn's non-inflamed
0
20
40
60
80
100
0.01 0.11 0.21
first pass Vp
no
rmal
ised
cu
mu
lati
ve f
req
uen
cyCrohn's non-inflamed
![Page 14: ISBE-AstraZeneca Strategic Alliance Project 26 Evaluation of Crohn’s disease using T1-weighted dynamic contrast- enhanced MRI (DCE-MRI) Karl Embleton](https://reader035.vdocuments.site/reader035/viewer/2022062304/56649f455503460f94c663d3/html5/thumbnails/14.jpg)
Multi-parameter segmentation
![Page 15: ISBE-AstraZeneca Strategic Alliance Project 26 Evaluation of Crohn’s disease using T1-weighted dynamic contrast- enhanced MRI (DCE-MRI) Karl Embleton](https://reader035.vdocuments.site/reader035/viewer/2022062304/56649f455503460f94c663d3/html5/thumbnails/15.jpg)
Recruitment increased to a second hospital
Reproducibility and measurement of treatment effects is required for next patients:
2 scans within 1 week prior to anti-inflammatory1 scan after 2 weeks treatment
Further work
Future possibilites could include:
Bowel motility measurements using ultra-fast SENSE imaging with contrast enhancement
CT perfusion and permeability